Congestive Heart Disease Marker Tests Market: By Product Type, By Test Type, Myoglobin, Troponins, Ischemia Modified Albumin, NT-proBNP or Brain Natriuretic Peptide or, Others), By Application, By End-user and By Region Forecast 2019-2030
Congestive Heart Disease Marker Tests Market size was valued at US$ 9.2 billion in 2023 poised to grow at a CAGR of 9% from 2024 to 2030. Congestive heart disease marker tests are diagnostic tests to measure the concentration of the protein to identify the occurrence and disease phase. The cardiac diseases can be prevented by identifying the heart conditions by cardiac biomarker testing is helpful for the immediate diagnosis and treatment. Cardiac biomarkers evaluate the cardiac function and help in identifying the severity and complexity of procedures to treat CVD. The primary indications for the CVD are acute coronary syndrome (ACS) that include congestive heart failure (CHF), angina pectoris (AP) peripheral artery disease (PAD), acute myocardial infarction (AMI) and others. The causes for CVD are include smoking, high blood pressure, diabetes, inadequate exercise, stress, unhealthy diet, obesity, high blood cholesterol, and alcoholism. The most commonly used cardiac biomarkers for diagnosis of CVD include troponin I and T, CK-MB, BNPs, myoglobin, and IMA, among others. Launch of new products, technological advancements, acquisitions and mergers, and collaborations are some key strategies followed by various industry players to increase their share in the congestive heart disease marker test market.
Study Period
2024-2030Base Year
2023CAGR
9%Largest Market
North-AmericaFastest Growing Market
Europe
Increase in geriatric population, rise in funding from private-public organizations for cardiac biomarkers research, and ongoing research and clinical trials for identification of the newer cardiac biomarkers are the key factors boost the global market over the forecast period. Moreover, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing, and increase in the adoption of new diagnostic tools by healthcare professionals and cost affordability for patients might propel the global market over the forecast period. However, factors technical problems such as sample collection and storage, stringent regulatory guidelines, lack of reimbursement systems hamper the growth of market over the forecast period.
Geographically, global market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the dominant share owing to increase in the prevalence of congestive heart failures (According to the American Heart Association (AHA), nearly five Mn individuals experience heart failure and about 550,000 new cases are diagnosed each year in the United States). Rising aging population, increase in inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders are the key factors expected to drive the market over the forecast period.
Europe holds a major share in global market attributed to increase in the prevalence of congestive heart failure (According to British Heart Foundation (BHF) approximately 7 Mn people are suffering from the various cardiovascular disease in U.K.). Rise in incidence of congestive heart disease in U.K. (approximately 4000 cases per year in new born babies), increase in the research and development, and novel innovations in congestive heart disease biomarker tests might fuel the growth of the market. The Asia-Pacific is expected to exhibit significant growth over forecast period owing to increase in prevalence of Myocardial Infarction, public and private initiatives to increase the awareness related to early cardiac disease diagnosis in physicians and patients.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 9.2 billion |
|
Market CAGR |
9% |
|
By Product Type |
|
|
By Test Type |
|
|
By Application |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The congestive heart disease marker tests market size was valued at US$ 9.2 billion in 2023 poised to grow at a CAGR of 9% from 2024 to 2030.
The key segments covered in the market are: by product type, test type, application, and end-users
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Congestive Heart Disease Marker Tests Market Introduction |
| 2.1.Global Congestive Heart Disease Marker Tests Market - Taxonomy |
| 2.2.Global Congestive Heart Disease Marker Tests Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Test Type |
| 2.2.3.Application |
| 2.2.4.End Users |
| 2.2.5.Region |
| 3. Global Congestive Heart Disease Marker Tests Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Congestive Heart Disease Marker Tests Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Congestive Heart Disease Marker Tests Market By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Reagents |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Kits |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Instruments |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Chemiluminescence |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Immunofluorescence |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. ELISA |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Immunochromatography |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6. Global Congestive Heart Disease Marker Tests Market By Test Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Myocardial muscle Creatine Kinase (CK-MB) |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Myoglobin |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Troponins (T and I) |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Ischemia Modified Albumin (IMA) |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. NT-proBNP or Brain Natriuretic Peptide (BNP) or |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Congestive Heart Disease Marker Tests Market By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Myocardial Infarction |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Acute Coronary Syndrome |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Congestive Heart Failure |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Atherosclerosis |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Global Congestive Heart Disease Marker Tests Market By End Users, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Clinics |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Diagnostic Centres |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Others |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9. Global Congestive Heart Disease Marker Tests Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. North America Congestive Heart Disease Marker Tests Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Reagents |
| 10.1.2.Kits |
| 10.1.3.Instruments |
| 10.1.4.Chemiluminescence |
| 10.1.5.Immunofluorescence |
| 10.1.6.ELISA |
| 10.1.7.Immunochromatography |
| 10.2. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Myocardial muscle Creatine Kinase (CK-MB) |
| 10.2.2.Myoglobin |
| 10.2.3.Troponins (T and I) |
| 10.2.4.Ischemia Modified Albumin (IMA) |
| 10.2.5.NT-proBNP or Brain Natriuretic Peptide (BNP) or |
| 10.2.6.Others |
| 10.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Myocardial Infarction |
| 10.3.2.Acute Coronary Syndrome |
| 10.3.3.Congestive Heart Failure |
| 10.3.4.Atherosclerosis |
| 10.3.5.Others |
| 10.4. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospitals |
| 10.4.2.Clinics |
| 10.4.3.Diagnostic Centres |
| 10.4.4.Others |
| 10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11. Europe Congestive Heart Disease Marker Tests Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Reagents |
| 11.1.2.Kits |
| 11.1.3.Instruments |
| 11.1.4.Chemiluminescence |
| 11.1.5.Immunofluorescence |
| 11.1.6.ELISA |
| 11.1.7.Immunochromatography |
| 11.2. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Myocardial muscle Creatine Kinase (CK-MB) |
| 11.2.2.Myoglobin |
| 11.2.3.Troponins (T and I) |
| 11.2.4.Ischemia Modified Albumin (IMA) |
| 11.2.5.NT-proBNP or Brain Natriuretic Peptide (BNP) or |
| 11.2.6.Others |
| 11.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Myocardial Infarction |
| 11.3.2.Acute Coronary Syndrome |
| 11.3.3.Congestive Heart Failure |
| 11.3.4.Atherosclerosis |
| 11.3.5.Others |
| 11.4. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospitals |
| 11.4.2.Clinics |
| 11.4.3.Diagnostic Centres |
| 11.4.4.Others |
| 11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12. Asia Pacific (APAC) Congestive Heart Disease Marker Tests Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Reagents |
| 12.1.2.Kits |
| 12.1.3.Instruments |
| 12.1.4.Chemiluminescence |
| 12.1.5.Immunofluorescence |
| 12.1.6.ELISA |
| 12.1.7.Immunochromatography |
| 12.2. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Myocardial muscle Creatine Kinase (CK-MB) |
| 12.2.2.Myoglobin |
| 12.2.3.Troponins (T and I) |
| 12.2.4.Ischemia Modified Albumin (IMA) |
| 12.2.5.NT-proBNP or Brain Natriuretic Peptide (BNP) or |
| 12.2.6.Others |
| 12.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Myocardial Infarction |
| 12.3.2.Acute Coronary Syndrome |
| 12.3.3.Congestive Heart Failure |
| 12.3.4.Atherosclerosis |
| 12.3.5.Others |
| 12.4. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospitals |
| 12.4.2.Clinics |
| 12.4.3.Diagnostic Centres |
| 12.4.4.Others |
| 12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13. Middle East and Africa (MEA) Congestive Heart Disease Marker Tests Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Reagents |
| 13.1.2.Kits |
| 13.1.3.Instruments |
| 13.1.4.Chemiluminescence |
| 13.1.5.Immunofluorescence |
| 13.1.6.ELISA |
| 13.1.7.Immunochromatography |
| 13.2. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Myocardial muscle Creatine Kinase (CK-MB) |
| 13.2.2.Myoglobin |
| 13.2.3.Troponins (T and I) |
| 13.2.4.Ischemia Modified Albumin (IMA) |
| 13.2.5.NT-proBNP or Brain Natriuretic Peptide (BNP) or |
| 13.2.6.Others |
| 13.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Myocardial Infarction |
| 13.3.2.Acute Coronary Syndrome |
| 13.3.3.Congestive Heart Failure |
| 13.3.4.Atherosclerosis |
| 13.3.5.Others |
| 13.4. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospitals |
| 13.4.2.Clinics |
| 13.4.3.Diagnostic Centres |
| 13.4.4.Others |
| 13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14. Latin America Congestive Heart Disease Marker Tests Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 14.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Reagents |
| 14.1.2.Kits |
| 14.1.3.Instruments |
| 14.1.4.Chemiluminescence |
| 14.1.5.Immunofluorescence |
| 14.1.6.ELISA |
| 14.1.7.Immunochromatography |
| 14.2. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Myocardial muscle Creatine Kinase (CK-MB) |
| 14.2.2.Myoglobin |
| 14.2.3.Troponins (T and I) |
| 14.2.4.Ischemia Modified Albumin (IMA) |
| 14.2.5.NT-proBNP or Brain Natriuretic Peptide (BNP) or |
| 14.2.6.Others |
| 14.3. Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Myocardial Infarction |
| 14.3.2.Acute Coronary Syndrome |
| 14.3.3.Congestive Heart Failure |
| 14.3.4.Atherosclerosis |
| 14.3.5.Others |
| 14.4. End Users Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospitals |
| 14.4.2.Clinics |
| 14.4.3.Diagnostic Centres |
| 14.4.4.Others |
| 14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.F. Hoffmann-La Roche (Switzerland) |
| 15.2.2.Siemens AG (Germany) |
| 15.2.3.Abbott Laboratories (U.S.) |
| 15.2.4.Danaher Corporation (U.S.) |
| 15.2.5.Nanogen, Inc. (U.S.) |
| 15.2.6.bioMerieux SA (France) |
| 15.2.7.Alere, Inc. (U.S.) |
| 15.2.8.LSI Medience Corporation (Mitsubishi Chemical Holdings Corporation, Japan) |
| 15.2.9.Randox Laboratories Ltd (U.K.) |
| 15.2.10.Ortho Clinical Diagnostics (The Carlyle Group (U.S.) |
| 15.2.11.Guangzhou Wondfo Biotech Co. Ltd. (China) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
